Eisai Inc., the U.S. pharmaceutical subsidiary of Japan’s Eisai Co. Ltd., officially relocated its U.S. headquarters from Woodcliff Lake to the ON3 complex in Nutley. The move brings approximately 800 jobs to the area and, at full capacity, the new state-of-the-art facility will accommodate 1,300 employees.
This move to 200 Metro Blvd. offers employees a dynamic, technologically advanced work environment that further enables Eisai’s commitment to innovation and the pursuit of its human health care mission to deliver life-changing therapies and health-related solutions to help people live healthier and more fulfilling lives.
The company’s U.S. presence also includes three early-stage discovery research centers, as well as commercial, clinical development and global demand organizations.
“Eisai’s decision to relocate to the ON3 campus is a demonstration of our ongoing commitment to New Jersey and to be part of this diverse life sciences hub,” said Tatsuyuki Yasuno, president, Eisai Inc. & Americas Region. “With a 400-seat auditorium and an Innovation Center at our new U.S. headquarters, we are establishing dedicated space and resources to educate and motivate our employees, as well as a forum to hear from patients, advocacy partners and the community. Through this collaboration, we can make a positive impact on people and society and fulfill our human health care mission.”
Read more from ROI-NJ:
“We recently met with the leadership of Eisai, and we were extremely impressed,” Nutley Mayor Mauro Tucci said. “Eisai is a global pharmaceutical company, committed to human health care, who values the communities where they work. We welcome Eisai to Nutley and look forward to working with them to enhance our township. We thank them for their investment in our community and the surrounding area.”
The ON3 campus straddles Nutley and Clifton.
“New Jersey has established itself as the global epicenter of the biopharmaceutical industry, and we are proud to see an innovative company like Eisai call Clifton home,” Clifton Mayor James Anzaldi said. “Given the urgency for new treatments for cancer and neurologic conditions, we look forward to seeing the important work Eisai is doing make a positive societal impact and improve the lives of our residents and people around the world.”